Systemic beta-blockers may reduce the need for repeated intravitreal injections in patients with wet age-related macular degeneration treated by bevacizumab

Retina

Volumn 33, Issue 3, 2013, Pages 508-512

  Montero, Javier A ^a   Ruiz Moreno, Jose M ^b,c   Sanchis Merino, Eugenia ^a   Perez Martin, Santiago ^a  

^a HOSPITAL UNIVERSITARIO RÍO HORTEGA   (Spain)

^b Alicante   (Spain)

^c UNIVERSITY OF CASTILLA LA MANCHA   (Spain)

Author keywords

age related macular degeneration; betaadrenergic blocking agents; bevacizumab; choroidal neovascularization; concomitant medication

Indexed keywords

ACENOCOUMAROL; ACETYLSALICYLIC ACID; ATENOLOL; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BEVACIZUMAB; BISOPROLOL; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LEVOBUNOLOL; NONSTEROID ANTIINFLAMMATORY AGENT; PROPRANOLOL; PROTON PUMP INHIBITOR;

ABSENCE OF SIDE EFFECTS; AGED; ANGINA PECTORIS; ARTICLE; CASE STUDY; CLINICAL ARTICLE; DRUG SAFETY; FAINTNESS; FEMALE; FOLLOW UP; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INTERVENTION STUDY; MALE; PHOTODYNAMIC THERAPY; RETINA FOVEA; RETINA MACULA AGE RELATED DEGENERATION; RETROSPECTIVE STUDY; SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY; SUBRETINAL NEOVASCULARIZATION; SYSTEMIC THERAPY; TREATMENT RESPONSE; VISUAL ACUITY;

ADRENERGIC BETA-ANTAGONISTS; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL, HUMANIZED; CALCIUM CHANNEL BLOCKERS; COMBINED MODALITY THERAPY; DIURETICS; FEMALE; FLUORESCEIN ANGIOGRAPHY; HUMANS; HYPERTENSION; INTRAVITREAL INJECTIONS; MALE; RETREATMENT; RETROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 84874950254     PISSN: 0275004X     EISSN: 15392864     Source Type: Journal    
DOI: 10.1097/IAE.0b013e3182695ba0     Document Type: Article

References (34)

1. Ferris FL 3rd, Fine SL, Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol 1984;102:1640-1642
2. Klein R, Klein BE, Jensen SC, et al. The five-year incidence and progression of age-related maculopathy: The Beaver Dam Eye Study. Ophthalmology 1997;104:7-21
3. Brantley MA Jr, Fang AM, King JM, et al. Association of complement factor H and LOC387715 genotypes with response of exudative age-related macular degeneration to intravitreal bevacizumab. Ophthalmology 2007;114:2168-2173
4. Heimes B, Lommatzsch A, Zeimer M, et al. Foveal RPE autofluorescence as a prognostic factor for anti-VEGF therapy in exudative AMD. Graefes Arch Clin Exp Ophthalmol 2008; 246:1229-1234
5. Martin DF, Maguire MG, Ying GS, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011;364:1897-1908
6. Bressler NM, Chang TS, Suner IJ, et al. Vision-related function after ranibizumab treatment by better- or worse-seeing eye: Clinical trial results from MARINA and ANCHOR. Ophthalmology 2010;117:747-756. e4
7. Abraham P, Yue H, Wilson L. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular agerelated macular degeneration: PIER study year 2. Am J Ophthalmol 2010;150:315-324. e1
8. Lalwani GA, Rosenfeld PJ, Fung AE, et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular agerelated macular degeneration: Year 2 of the PrONTO Study. Am J Ophthalmol 2009;148:43-58. e1
9. Schmidt-Erfurth U, Eldem B, Guymer R, et al. Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: The EXCITE study. Ophthalmology 2011;118:831-839
10. Holz FG, Amoaku W, Donate J, et al. Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular agerelated macular degeneration: The SUSTAIN study. Ophthalmology 2011;118:663-671
11. Forte R, Bonavolonta P, Benayoun Y, et al. Intravitreal ranibizumab and bevacizumab in combination with full-fluence ver- Teporfin therapy and dexamethasone for exudative age-related macular degeneration. Ophthalmic Res 2011;45:129-134
12. Ruiz-Moreno JM, Montero JA, Zarbin MA. Photodynamic therapy and high-dose intravitreal triamcinolone to treat exudative age-related macular degeneration: 2-year outcome. Retina 2007;27:458-461
13. Sivaprasad S, Patra S, DaCosta J, et al. A pilot study on the combination treatment of reduced-fluence photodynamic therapy, intravitreal ranibizumab, intravitreal dexamethasone and oral minocycline for neovascular age-related macular degeneration. Ophthalmologica 2011;225:200-206
14. Amrite A, Pugazhenthi V, Cheruvu N, et al. Delivery of celecoxib for treating diseases of the eye: Influence of pigment and diabetes. Expert Opin Drug Deliv 2010;7:631-645
15. Weil J, Benndorf R, Fredersdorf S, et al. Norepinephrine upregulates vascular endothelial growth factor in rat cardiac myocytes by a paracrine mechanism. Angiogenesis 2003;6:303-309
16. Fredriksson JM, Lindquist JM, Bronnikov GE, et al. Norepinephrine induces vascular endothelial growth factor gene expression in brown adipocytes through a beta -Adrenoreceptor/cAMP/protein kinase A pathway involving Src but independently of Erk1/2. J Biol Chem 2000;275: 13802-13811
17. Hajighasemi F, Hajighasemi S. Effect of propranolol on angiogenic factors in human hematopoietic cell lines in vitro. Iran Biomed J 2009;13:223-228
18. Ristori C, Filippi L, Dal Monte M, et al. Role of the adrenergic system in a mouse model of oxygen-induced retinopathy: Antiangiogenic effects of beta-Adrenoreceptor blockade. Invest Ophthalmol Vis Sci 2011;52:155-170
19. Martini D, Monte MD, Ristori C, et al. Antiangiogenic effects of beta2 -Adrenergic receptor blockade in a mouse model of oxygen-induced retinopathy. J Neurochem 2011;119:1317-1329
20. Ricci B, Ricci F, Maggiano N. Oxygen-induced retinopathy in the newborn rat: Morphological and immunohistological findings in animals treated with topical timolol maleate. Ophthalmologica 2000;214:136-139
21. Wester ST, Johnson TE. Echographic evidence of regression of a periocular infantile capillary hemangioma treated with systemic propranolol. Ophthalmic Surg Lasers Imaging 2011; 42 Online. e18-e21
22. Fabian ID, Ben-Zion I, Samuel C, et al. Reduction in astigmatism using propranolol as first-line therapy for periocular capillary hemangioma. Am J Ophthalmol 2011;151:53-58
23. Al Dhaybi R, Superstein R, Milet A, et al. Treatment of periocular infantile hemangiomas with propranolol: Case series of 18 children. Ophthalmology 2011;118:1184-1188
24. Sidbury R. Update on vascular tumors of infancy. Curr Opin Pediatr 2010;22:432-437
25. Mishra A, Holmes WJ, Gorst C, et al. Role of propranolol in the management of periocular hemangiomas. Plast Reconstr Surg 2010;126:671
26. Maturo S, Hartnick C. Initial experience using propranolol as the sole treatment for infantile airway hemangiomas. Int J Pediatr Otorhinolaryngol 2010;74:323-325
27. Li YC, McCahon E, Rowe NA, et al. Successful treatment of infantile haemangiomas of the orbit with propranolol. Clin Exp Ophthalmol 2010;38:554-559
28. Jadhav VM, Tolat SN. Dramatic response of propranolol in hemangioma: Report of two cases. Indian J Dermatol Venereol Leprol 2010;76:691-694
29. Haider KM, Plager DA, Neely DE, et al. Outpatient treatment of periocular infantile hemangiomas with oral propranolol. J AAPOS 2010;14:251-256
30. Nguyen J, Fay A. Pharmacologic therapy for periocular infantile hemangiomas: A review of the literature. Semin Ophthalmol 2009;24:178-184
31. Loffler H, Kosel C, Cremer H, et al. Die Propranolol-Therapie in der Behandlung problematischer Hämangiome. Eine neue Standardtherapie kündigt sich an. Hautarzt 2009;60:1013-1016
32. Filippi L, Cavallaro G, Fiorini P, et al. Study protocol: Safety and efficacy of propranolol in newborns with Retinopathy of Prematurity (PROP-ROP): ISRCTN18523491. BMC Pediatr 2010;10:83
33. Smith C, Teitler M. Beta-blocker selectivity at cloned human beta 1- And beta 2-Adrenergic receptors. Cardiovasc Drugs Ther 1999;13:123-126
34. Dayani PN, Siddiqi OK, Holekamp NM. Safety of intravitreal injections in patients receiving warfarin anticoagulation. Am J Ophthalmol 2007;144:451-453